Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, CSR

BioMarin Announces First Recipients of RARE Scholars Scholarship Program


SAN RAFAEL, Calif., June 28, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has awarded the first five recipients of the RARE Scholars program, an annual scholarship for students living with rare disease. The RARE Scholars program provides up to $20,000 to students living with mucopolysaccharidoses, phenylketonuria or Batten disease.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

"We are thrilled to offer this scholarship program for the first time to students with rare genetic diseases, who have not only excelled academically, but also have overcome enormous challenges," said Jean-Jacques Bienaimé, chairman and chief executive officer of BioMarin. "We are inspired to offer scholarships to students who have excelled in spite of a disease diagnosed in childhood. It is an honor to be a part of their journeys into adulthood."

The recipients of the 2018 RARE Scholars program are:

"It's amazing to see members of our community receiving these scholarships and attending college, especially because for a condition like PKU, their disease can impair their ability to learn," said Christine Brown, MS, executive director of the National PKU Alliance. "Higher education is so important, and we are thankful to BioMarin for offering this scholarship to further help people living with a rare disease."

BioMarin announced its RARE Scholars program on Rare Disease Day, February 28, 2018 and began accepting applications the next day.

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

About RARE Scholars
RARE Scholars aims to empower patients with continued education by recognizing students living with rare diseases who have demonstrated leadership and participation in school and community activities. The RARE Scholars program distributes up to $20,000 each year, awarding $5,000 for undergraduate four-year or graduate studies or $2,500 for two-year or vocational-technical studies. Applicants must be accepted to or a current student in a postsecondary or graduate level program and diagnosed with mucopolysaccharidoses (MPS), phenylketonuria (PKU) or Batten disease. In March 2019, qualified students may submit an application here for the 2019/2010 school year. 

Contacts:


Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.


These press releases may also interest you

at 06:37
In the news release, OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market, issued 22-Apr-2024 by OSR Holdings over PR Newswire, we are...

at 06:21
Beyond2020, the flagship initiative launched by the Zayed Sustainability Prize, the UAE's pioneering award for sustainability and humanitarianism, today announced the deployment of AI-powered mammography services across Costa Rica to support the...

at 06:18
Surrey FA and Chelsea FC Foundation are proud to announce their collaborative effort once again to offer empowering coaching sessions to female refugees in the local community. These sessions will provide an opportunity for women to engage with...

at 06:05
BeiGene, Ltd. , a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use....

at 06:05
Vizient, Inc. hosted its inaugural Insight: Cell, Gene, and Specialty Pharmacy Symposium, bringing together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals along with other stakeholders to discuss...

at 06:05
SprintRay, the leader in dental 3D printing, unveiled the Company's most significant innovation to-date to over 250 dental professionals at 3DNext, their summit in Miami. The Midas Digital Press 3D Printer is poised to not only transform dental...



News published on and distributed by: